|
Topics in Evidence-Based Pharmacy Practice
11/28/2011: Exemestane for Breast Cancer Prevention
Bradi L. Frei
Feik School of Pharmacy, University of the Incarnate Word, San Antonio, Texas
Janice Joseph
Feik School of Pharmacy, University of the Incarnate Word, San Antonio, Texas
Kimberly Martin
Feik School of Pharmacy, University of the Incarnate Word, San Antonio, Texas
Excerpt:"Approximately 230,480 new cases of breast cancer were diagnosed in the United States in 2011.1 Improved methods of prevention are needed. There are only two Food and Drug Administration approved pharmacologic options - tamoxifen and raloxifene - for the prevention of breast cancer in high risk, postmenopausal women. The MAP.3 trial provides new information about the aromatase inhibitor exemestane.2 It establishes that exemestane can be used effectively and safely to reduce the risk of invasive breast cancer in postmenopausal women...."
|
|
|
|
|